Apixaban (Anticoagulation for AFib-related stroke)

Treatment for Ischemic stroke

Typical Dosage: 5 mg BID

Effectiveness
70%
Safety Score
65%
Clinical Trials
10
Participants
70K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg BID
Time to Effect
days
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
30(Treat 30 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,000
Monitoring:$150
Side Effect Mgmt:$300
Total Annual:$6,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$45,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$9,923
Comparison vs Warfarin
Cost Difference
+$5,500/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Apixaban (Anticoagulation for AFib-related stroke) Outcomes

for Ischemic stroke

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+65%
Common Side Effects
Major bleeding (ICH, GI)
+2%
Minor bleeding
+15%

Sources:

ahajournals.org
semanticscholar.org
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov